Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is a cohort observational, retrospective, non-interventional study.
Study period:
Index date: The index date were defined as the first date of the first prescription of Sacubitril/Valsartan during inclusion period and this were used to establish the beginning of the follow-up period.
Characterization period: 6 months period before the index date were used to characterize patients.
Follow-up period: Any patients has at least 1 year of follow-up. Follow-up period went from index date to June 2020.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sacubitril/Valsartan | Heart Failure (HF) patients treated with Sac/Val |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sacubitril/Valsartan | Drug | HF patients treated with Sac/Val |
|
| Measure | Description | Time Frame |
|---|---|---|
| Age | To describe the demographics | Baseline |
| Gender | To describe the demographics | Baseline |
| Number of patients with Ischemic heart disease | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with PCI/CABG: Percutaneous coronary intervention/coronary artery bypass grafting | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with moderate or severe mitral or aortic valvulopathy | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with Implanted prosthetic valve | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with ICD/CRT, Implantable Cardioverter Defibrillator/ Cardiac Resynchronization Therapy | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with Atrial fibrillation | To evaluate clinical characteristics at baseline. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with initial and final doses | To evaluate the Sacubitril/Valsartan dosing pattern during follow-up | throughout the study, approximately 3 years |
| Number of patients with Non-maximum dose |
Not provided
Inclusion Criteria:
Consecutive ambulatory patients with a diagnosis of HF that attended the Outpatient Clinics for HF management and who have been prescribed Sacubitril/Valsartan from 01 October 2016 to 30 June 2019 (inclusion period) were included in the study. To allow for at least 1-year follow-up period for any patients, the observation period ended by 30 June 2020.
In detail, all patients attending by outpatient clinics for the diagnosis and treatment of HF in the Italian Centers involved, with:
Exclusion Criteria:
Not provided
Not provided
Heart Failure with reduced Ejection Fraction (HfrEF) patients treated with Sacubitril/Valsartan.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Trieste | 934125 | Italy |
Not provided
| Label | URL |
|---|---|
| Results for CLCZ696BIT08 from the Novartis Clinical Trials Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C549068 | sacubitril and valsartan sodium hydrate drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of patients with prior hospitalization for HF | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with previous stroke | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with diabetes mellitus | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with Hypertension | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with Chronic kidney disease (CKD) | To evaluate clinical characteristics at baseline. | Baseline |
| Duration of HF disease | To evaluate clinical characteristics at baseline. | Baseline |
| Number of patients with pharmacological treatments for HF | To evaluate the pharmacological treatments for HF during characterization and follow-up. | throughout the study, approximately 3 years |
To evaluate the Sacubitril/Valsartan dosing pattern during follow-up
| throughout the study, approximately 3 years |
| Time to maximal dose prescribed | To evaluate the Sacubitril/Valsartan dosing pattern during follow-up | throughout the study, approximately 3 years |
| Number of patients with hospitalization HF-related | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of patients with hospitalization related to other cardiovascular events | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of patients with hospitalization related to non-CV cause | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of patients with Percutaneous Coronary Intervention (PCI)/coronary artery bypass grafting (CABG) | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of patients with Valvular intervention | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of patients with Device implantation (ICD/CRT) | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of patients with ER visits HF-related | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |
| Number of deaths | To evaluate frequency of cardiovascular (CV) and non-CV death. | throughout the study, approximately 3 years |